NLS Pharma Is Awarded "Best Quality of Life Improvement Pharmaceuticals Company – Central Europe" by Global Health & Pharma Magazine

Mazindol CR is recognized as a potential game-changing future treatment for ADHD

Switzerland, March 24, 2018 - NLS-1 Pharma AG (NLS), a Swiss biotech firm focusing on the development of novel treatments for Attention-Deficit/Hyperactivity Disorder (ADHD), announced their selection as the winner of a prestigious 2018 Biotechnology Award by Global Health & Pharma (GHP) magazine. In the press release announcing the winners, GHP stated "The awards are given solely on merit and are awarded to commend those most deserving for their ingenuity and hard work, distinguishing them from their competitors and proving them worthy of recognition."

"Everyone at NLS is grateful for the recognition by Global Health & Pharma, a respected industry publication with circulation exceeding 260,000 worldwide," said Alex Zwyer, CEO of NLS. "We believe this award recognizes the differentiation of mazindol CR, our potentially game-changing investigational treatment for the millions of patients suffering with ADHD. We'd like to thank the many researchers and patients that have contributed to our clinical results to date and are committed to progress the development of this much needed alternative to schedule II stimulants".

A recent phase 2 study provided the first evidence that mazindol CR is efficacious and well tolerated in adults with ADHD. Mazindol CR had a robust effect on ADHD symptoms, with a large placebo-adjusted effect size of 1.09. The magnitude of this effect was comparable to what is typically seen with stimulants, such as methylphenidate CR, lisdexamfetamine, d-amphetamine extended release (XR), and mixed amphetamine salts, and much higher than for atomoxetine. In addition, onset of action was rapid; separation from placebo was seen at the first post-treatment data point, after 1 week of treatment.

About NLS Pharma

NLS-1 Pharma AG (NLS) is a privately owned, Swiss-based biotech firm focusing on the development of first-in-class treatments for ADHD. NLS has built a portfolio of promising clinical-stage medicines being developed by an experienced team of proven experts in ADHD and working closely with key opinion leaders globally.

About Mazindol

Mazindol immediate release is an imidazo-isoindole agent, originally developed as an appetite suppressant in 1973, and classified at that time as a C4 controlled substance (low probability for misuse/abuse). It was withdrawn from US markets by 2002 due to commercial reasons unrelated to efficacy or safety. Mazindol controlled release is a novel formulation with a lower Cmax than the immediate release formulation and an equivalent AUC, designed for once daily dosing, which is under investigation for the treatment of ADHD and narcolepsy.

Investor relations & media contact

NLS-1 Pharma AG
Alex Zwyer, CEO : +41 41 618 80 00

www.nlspharma.com